GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

Inicio・Lista de Acciones・Ocugen Inc

Ocugen Inc

Cerrado

1.79 3.47

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.78

Máximo

1.79

Métricas clave
By Trading Economics
Ingresos	2.3M -18M
Ventas	-1.9M -193K
Margen de beneficios	9,174.093
Empleados	116
EBITDA	1.5M -16M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+566.49% upside

Dividendos
By Dow Jones
Próximas Ganancias	8 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-8.7M 626M
Apertura anterior	-1.68
Cierre anterior	1.79

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

0.6818 / 0.74 Soporte y Resistencia

Ocugen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 may 2026, 23:43 UTC

Noticias de Eventos Importantes

New Zealand's Unemployment Rate Falls in 1Q

5 may 2026, 23:20 UTC

Acciones populares

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 may 2026, 21:48 UTC

Ganancias

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 may 2026, 21:05 UTC

Adquisiciones, fusiones, absorciones

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 may 2026, 00:00 UTC

Charlas de Mercado

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 may 2026, 23:39 UTC

Charlas de Mercado

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 may 2026, 22:26 UTC

Charlas de Mercado

AMD Data-Center Business Continues to Surge -- Market Talk

5 may 2026, 22:20 UTC

Charlas de Mercado

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 may 2026, 22:08 UTC

Ganancias

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 may 2026, 22:07 UTC

Ganancias

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:48 UTC

Ganancias

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 may 2026, 21:48 UTC

Ganancias

Pan American Silver 1Q Rev $1.2B >PAAS

5 may 2026, 21:42 UTC

Ganancias

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 may 2026, 21:38 UTC

Ganancias

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:30 UTC

Ganancias

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 may 2026, 21:29 UTC

Ganancias

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:26 UTC

Ganancias

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 may 2026, 21:25 UTC

Ganancias

Alcon Inc. 1Q EPS 39c >ALC.EB

5 may 2026, 21:25 UTC

Ganancias

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 may 2026, 21:24 UTC

Ganancias

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:18 UTC

Ganancias

Mistras Backs 2026 Rev $730M-$750M >MG

5 may 2026, 21:17 UTC

Ganancias

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 may 2026, 21:15 UTC

Ganancias

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 may 2026, 21:12 UTC

Ganancias

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 may 2026, 21:11 UTC

Ganancias

SSR Mining 1Q Rev $581.8M >SSRM

5 may 2026, 21:10 UTC

Ganancias

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 may 2026, 21:10 UTC

Ganancias

SSR Mining 1Q EPS $1.16 >SSRM

5 may 2026, 21:08 UTC

Ganancias

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 may 2026, 21:01 UTC

Ganancias

Intact Financial 1Q EPS C$4.12 >IFC.T

5 may 2026, 21:01 UTC

Acciones populares

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Comparación entre iguales

Cambio de precio

Ocugen Inc previsión

Precio Objetivo

By TipRanks

566.49% repunte

Estimación a 12 Meses

Media 12.33 USD 566.49%

Máximo 22 USD

Mínimo 8 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocugen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Ocugen Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.6818 / 0.74Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.